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Although universally recognized as the source of cerebrospinal fluid (CSF), the choroid plexus (ChP) has been one of the most under-
studied tissues in neuroscience. The reasons for this aremultiple and varied, including historical perceptions about passive and permis-
sive roles for theChP, experimental issues, and lackof clinical salience.However, recentworkon theChPand instructive signals in theCSF
have sparked new hypotheses about how the ChP and CSF provide unexpected means for regulating nervous system structure and
function in health and disease, as well as new ChP-based therapeutic approaches using pluripotent stem cell technology. This minisym-
posium combines new and established investigators to capture some of the newfound excitement surrounding the ChP-CSF system.
Introduction
Almost 100 years ago to date, Harvey Cushing made the seminal
discovery that the choroid plexus (ChP), a highly vascularized
tissue located in each ventricle of the brain, secretes cerebrospinal
fluid (CSF) (Cushing, 1914), casting aside lingering views of the
CSF as a possible postmortem precipitate. In humans, the ChP
produces 400–600 ml of CSF each day, which is enough to turn
over the CSF 3–4 times. The CSF then flows from the lateral
ventricles to the third and fourth ventricles, and then into the
subarachnoid space of the brain and spinal cord via openings
(foramena) below the cerebellum (Fig. 1). The CSF returns to the
peripheral circulation via resorption by arachnoid granulations
in venous sinuses of the brain (Segal, 2005). The ChP-CSF there-
fore represents an independent circulatory system for the brain
and spinal cord.
The ChP-CSF system is also unique in terms of how under-
studied it has been. A reflection of this comes from last year’s
Society for Neuroscience meeting: of the 17,255 searchable ab-
stracts, only 9 had “choroid plexus” in the title or as a keyword.
Why is that? Part of the answer may relate to the generally per-
ceived “uninteresting” functions historically attributed to the
CSF, such as providing buoyancy and acting as a passive sink for
waste. The ChP has also had limited salience in the clinical arena.
ChP pathology in most neurological or psychiatric conditions is
nonspecific (atrophy or accelerated atrophy), and apart from un-
common types of hydrocephalus, the ChP is not known to be
responsible for primary symptoms or particularly helpful for dif-
ferential diagnosis. There have also been experimental barriers,
including a relative lack ofChP-selective tools, difficulties obtain-
ing CSF from small animal models, and challenges inherent in
studying a fluid rather than a tissue.
Recent advances, however, have begun to transform our view
of the ChP-CSF system. Newer techniques indicate that CSF is a
rich source of proteins, lipids, hormones, cholesterol, glucose,
microRNAs, and many other molecules and metabolites that in-
fluence a multitude of CNS functions, including neurogenesis in
embryos and adults (Dziegielewska et al., 1981; Zappaterra et al.,
2007; Lehtinen andWalsh, 2011; Zappaterra and Lehtinen, 2012;
Burgos et al., 2013). Spurred by the clinical utility of CSF bio-
markers for Alzheimer’s disease, there is tremendous interest in
CSF biomarker discovery for the diagnosis and management of
CNS disorders, and the ability to derive secretory ChP cells from
embryonic stem cells sets the stage for unique ChP-based
strategies for treating a host of CNS diseases. In this minire-
view, we highlight some of the new roles and emerging prin-
ciples for the ChP-CSF system in the areas of development,
disease, and therapy.
Choroid plexus development
Only recently have investigators begun to usemodern techniques
to study development of the ChP itself. The ChP forms at and
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adjacent to the embryonic dorsal midline in the hindbrain, dien-
cephalon, and telencephalon. Whereas ChP stroma has mesen-
chymal origins, including meningeal cells, ChP epithelial cells
(CPECs) are derived from neuroepithelium, and important as-
pects of CPEC specification are now understood. Genetic lineage
analyses indicate that CPECs originate from the roof plate (Awa-
tramani et al., 2003; Currle et al., 2005; Hunter and Dymecki,
2007), a well-known signaling center in early CNS development.
Roof plate cells differentiate directly into CPECs at all four ChP
sites, although in the telencephalon, most CPECs are induced
indirectly by the roof plate (Bailey, 1915; Currle et al., 2005), and
multiple studies implicate bone morphogenetic proteins as the
instructive roof plate-derivedmolecules for CPEC fate (Hebert et
al., 2002; Cheng et al., 2006; Fernandes et al., 2007; Watanabe et
al., 2012). CPEC differentiation is evident before definitive neu-
rogenesis or ependymal differentiation ensues, and in vivo and in
vitromouse studies indicate that CPEC competency is restricted
to early-stage neuroepithelial cells in the telencephalon and roof
plate regions (Thomas andDziadek, 1993;Watanabe et al., 2012).
Other studies have begun to clarify the epithelial–mesench-
mymal interactions involved in ChP development. Recent ge-
netic experiments in the mouse embryo (Huang et al., 2009;
Nielsen and Dymecki, 2010) reveal a central role for the secreted
morphogen Sonic Hedgehog (Shh) in coordinating the develop-
mental challenge ofmatchingCPECnumbers to vasculature. The
critical source of Shhwas found to be embryonicCPECs (Bitgood
and McMahon, 1995; Huang et al., 2009; Nielsen and Dymecki,
2010) (Fig. 2). The responding cell populations were found to be
the perivascular cells (pericytes) in the underlying ChP vascular
bed (Nielsen andDymecki, 2010), and the progenitor cells for the
ChPe located laterally (Huang et al., 2009). CPECs are postmi-
totic, expanding through cell addition supplied by progenitor
cells residing in the lateral periphery of the hindbrain ChP, in a
territory situated in neuroectoderm and demarcatedmolecularly
by expression of the transcription factor Lmx1a and the secreted
signaling molecule Gdf7 (Currle et al., 2005; Landsberg et al.,
2005; Hunter and Dymecki, 2007; Chizhikov et al., 2010). Thus,
although Shh is present in CSF, here it acts on cell populations
constituent to, even internal to, the ChP, suggesting Shh release
across the basal surface of the epithelium to deepermesenchymal
cells like pericytes, as opposed to only apical release into the CSF.
Shh, acting on these two cell populations (pericytes andCPEC
progenitor cells), was found to regulate at least two key processes:
outgrowth of vasculature in the ChP and enhanced CPEC gener-
ation from their neurectodermal progenitor pool to ensheath
that expanding vasculature. In the absence of CPEC-produced
Shh, a severely hypoplastic structure develops, deficient in CPEC
and vasculature, as well as showing reduced folding of the ChP
surface (Huang et al., 2009; Nielsen and Dymecki, 2010). Shh
thus appears to orchestrate the codevelopment of two disparate
cell lineages during ChPmorphogenesis: underlying perivascular
cells and more distant CPEC progenitor cells. The relative con-
tribution of each of these Hh-responsive populations to overall
ChP development remains to be delineated and is an area of
active investigation. For example, it seems straightforward that
pericyte action in response to Shh likely enables vascular expan-
sion and outgrowth, but pericytes may also serve, via factor se-
cretion, to boost CPEC production from the neuroectodermal
progenitor pool. Answers to these possibilities await additional
manipulations of Shh pathway genes, restricted to pericytes ver-
sus CPEC progenitors.
CSF and distribution of instructive cues in development
Beyond development of the ChP itself, recent studies have begun
to delineate how the embryonic ChP regulates development of
the rest of the brain. The earliest born neural stem cells in the
developing cerebral cortex are located along CSF-filled ventricles
(Fig. 3A). A number of genes that directly regulate cortical pro-
genitor cell proliferation andmigration have been identified, and
most of these genes are expressed by cortical progenitor cells
(Thornton and Woods, 2009; Manzini and Walsh, 2011). The
large literature on brain development also demonstrates critical
roles that extrinsic cues, including growth factors and morpho-
gens (e.g., Fgf, Bmps, Shh, Wnt, and RA), have on cortical pro-
genitor cells (for review, see Lehtinen and Walsh, 2011; Tiberi et
al., 2012). Yet the evidence from the majority of these studies has
never fully explained how these signals access cortical progenitors
at the ventricular surface, where the primary access to signals is
likely via the CSF. Recent studies have begun to probe this ques-
tion and, indeed, have demonstrated that secreted signals ema-
nating from the CSF provide growth-promoting signals to neural
stem cells (Lehtinen et al., 2011).
Embryonic CSF, without any additional exogenous growth-
promoting signals, can promote the development and growth of
neural stem cells and cortical explants, and the favorable effects of
CSF are age-dependent (Lehtinen et al., 2011). For example,
young stem cells bathed in embryonic CSF divide robustly. By
contrast, the same stem cells bathed in CSF obtained at other
ages, including adult CSF, display only limited cell division.
These results agree with findings that many protein signals in the
CSF fluctuate with age. For instance, CSF-insulin-like growth
factor-2 (IGF2) levels, attributed largely to ChP secretion, peak
during brain development. CSF-IGF2 stimulates cell division by
binding to receptors on the surface of neural stem cells (Lehtinen
et al., 2011). Intracerebroventricular injections of IGF1, IGF1-
neutralizing antibodies, and IGF1R inhibitors further demon-
strate that IGF signals delivered by the embryonic CSF stimulate
proliferative events in the cortical ventricular zone (Mairet-
Coello et al., 2009). Finally, mouse genetic approaches have fur-
ther shown that IGF2 regulates neurogenesis, formation of the
uppermost layers of the cerebral cortex, and brain size (Lehtinen
et al., 2011).
Intriguingly, when neural stem cells lose their distinct polar-
ity, including genetic manipulation of the polarity gene Pals1
Figure 1. CSF secretion and flow. The CSF is secreted by the choroid plexus, a tissue located
in each ventricle in the brain. CSF flows from the lateral ventricles to the third and fourth
ventricles, then into the subarachnoid space of the brain and spinal cord via openings (fora-
mena) below the cerebellum. CSF is then resorbed into the peripheral circulation by arachnoid
granulations in venous sinuses of the brain.
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(Kim et al., 2010; Lehtinen et al., 2011) or the ciliary gene Arl13b
(Higginbotham et al., 2013), they share a striking deficiency in
IGF signaling receptors and decreased IGF signaling pathway ac-
tivation on the apical surface of neural stem cells. Recent evidence
indicates that IGF1 binding to the IGF1R on primary cilia of
radial glial progenitor cells accelerates G1-S progression and cili-
ary resorption by a noncanonical G signaling pathway (Yeh et
al., 2013). Thus, the intrinsic regulation of apical morphology as
well as ciliogenesis may be crucial for the capacity of apical pro-
genitors to access and respond to CSF-distributed signals. Im-
paired primary cilia are associated with a number of central
nervous system disorders. These findings also resonate with ob-
servations from the development of other organs, where muta-
tions at the primary cilium can lead to a wide range of
physiological disruptions ranging from the mirroring of internal
organs in situs inversus, to polycystic kidney disease (for review,
see Louvi and Grove, 2011).
Primary cilia are known to relay several additional extrinsic
signals to cell bodies, including Shh (Huangfu et al., 2003), Fgfs
(Neugebauer et al., 2009), and Wnt (Gerdes et al., 2007; for re-
view, see Eggenschwiler and Anderson, 2007). Together with ob-
servations that active signaling pathway components are
enriched at the apical, ventricular surface, for instance, phospho-
tyrosine (Chenn et al., 1998), phospho-AKT (Poduri et al., 2012),
and phospho-MAPK (Toyoda et al., 2010), these findings have
sparked investigations into which additional instructive cues are
received by progenitor cells from the CSF. To this end, advances
in proteomic tools, including mass spectrometry, have allowed
for an improved characterization of the CSF proteome. We now
know that, in addition to secreted growth factors and morpho-
gens, the CSF is home to cytokines, extracellular matrix proteins,
binding proteins, adhesion molecules, and many others factors
whose availabilities and activities are tightly regulated by the
ChP-CSF system (Parada et al., 2005; Redzic et al., 2005; Martín
et al., 2006; Zappaterra et al., 2007; Huang et al., 2010; Lehtinen
andWalsh, 2011). Overall, these studies have demonstrated that,
rather than being merely a fluid cushion for the brain with vari-
ous proteins passively oozing into and
out of the CSF, the embryonic ChP-CSF
system actively distributes secreted sig-
nals to developing progenitor cells, in-
structing cerebral cortical development.
CSF and instructive cues for
adult neurogenesis
ChP-CSF regulation of neural progenitors
has now been implicated not only in em-
bryos, but also in adults. Neurogenesis
persists into adulthood in select brain re-
gions in most mammals, namely, the sub-
granular zone of the dentate gyrus and the
subventricular zone (SVZ) of the lateral
ventricles (Temple and Alvarez-Buylla,
1999). Within the SVZ, neural progenitor
cells (NPCs), which include neural stem
cells and other types of progenitor cells,
give rise to neuroblasts that migrate to
produce olfactory bulb interneurons
throughout life (Doetsch et al., 1997). In-
trinsic and extrinsic cues within the SVZ
stem cell niche govern NPC self-renewal
and differentiation (Doetsch, 2003). For
example, several key morphogens that in-
fluence neurogenesis in the adult SVZ are known to be synthe-
sized by the ChP, including EGF (Tropepe et al., 1997; Enwere et
al., 2004), FGF-2 (Redzic et al., 2005), and retinoic acid (Haskell
and LaMantia, 2005). A subpopulation of SVZ NPCs is situated
to receive signals from the CSF via apical processes that span the
ependymal layer and project into the ventricular space (Mirzadeh
et al., 2008; Shen et al., 2008). In the mouse, these projections are
enriched in the signaling/adhesion receptor VCAM1, which is
important for maintaining niche architecture and NPC lineage
progression, and is sensitive to changes in environmental cyto-
kines, such as IL-1 produced by the ChP (Kokovay et al., 2012).
The immediate proximity of the ChP to the SVZ has led to in-
creasing interest in defining in-depth the role of this tissue in
adult neurogenesis (Falcao et al., 2012).
With aging, neurogenesis declines, leading to fewer new olfac-
tory bulb interneurons and deficits in fine olfactory discrimina-
tion (Tropepe et al., 1997; Enwere et al., 2004). SVZ architecture
is disrupted (Shook et al., 2012), and the number of SVZ NPCs
dwindles. The ChP also undergoes dramatic changes during the
course of aging. Morphological changes in the ChP epithelium
mirror declining fluid transport and protein synthesis (Redzic et
al., 2005; Chen et al., 2012), including reduced production of
growth factors that are known to impact neurogenesis (Emerich
et al., 2007). Addition of growth factors secreted by the ChP,
including EGF (Tropepe et al., 1997; Enwere et al., 2004) and
FGF-2 (Redzic et al., 2005), can partially revitalize neurogenesis
in aged mice.
Current research is investigating the influence of extrinsic
cues on SVZ structure and function throughout adulthood, and
in particular in how ChP-derived factors impact and contribute
to age-related changes in niche architecture and neurogenic out-
put. Long-term time-lapse imaging of ChP explants cocultured
with isolated, single SVZ NPCs enables the visualization of ChP
impact on NPC clonal development, and the analysis of hetero-
chronic combinations of young ChP with aged SVZ and vice
versa. Single-cell, clonal time-lapse analysis also yields detailed
information on cell behavior, survival, differentiation, and divi-
Figure 2. Overview of ChP-CSF–brain interactions. In addition to secreting CSF, ChP epithelial cells secrete morphogens and
proteins with sites of actionwithin the ChP (e.g., Shh on vasculature and ChP progenitor cells) and beyond the ChP on neural stem
cells (e.g., IGF2 on cerebral cortical progenitor cells, and cytokines on adult neural stem cells). The ChP can be the site of tumori-
genesis (brown). It also plays a role in protecting the brain from A toxicity. Because there is an exchange between the brain’s
interstitial fluid and CSF (perforated line), the ratio of phosphorylated Tau:A provides an early diagnostic for Alzheimer’s disease
and canpredict the severity of neurodegenerative decline. Recent advances havemadepossible the engineering andproduction of
ES-derived ChP epithelial cells (green).
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sion rate. Initial in vitro 2-D coculture
studies demonstrate that cell behavior and
clonal output are stimulated in the pres-
ence of ChP tissue in both young and aged
SVZ cells, with preservation of the NPC
state and inhibition of differentiation. Ef-
forts to identify the factors responsible for
regulating neurogenesis through ChP-
conditioned media analysis and transcrip-
tome studies are currently underway.
Choroid plexus tumors
Aswith virtually all tissues of the body, the
ChP can be a target for cancer as well.
CPECs are the presumed cells of origin for
most ChP tumors, although rare intra-
ventricular meningiomas are thought to
arise from neoplastic meningeal cells in
ChP stroma. Although tumors of the ChP
are rare in children and adults, accounting
for 2% of all pediatric brain tumors
(CBTRUS, 2006; Paulus and Brandner,
2007), they are most commonly observed
in infants (accounting for 10–20% of
brain tumors in infants in their first year;
median age of diagnosis, 3.5 years) (Safaee
et al., 2013) (Fig. 2). Efforts to assemble
the critical mass of patients and experts
necessary to advance cures of the disease
have proved relatively unsuccessful, and
treatment options and survival rates
remain limited (Wolff et al., 2002; Lafay-
Cousin and Strother, 2009). Recent devel-
opments have innovated a cross-species
genomics approach that allows mapping
of the cells of origin of childhood brain
tumors. Targeting these cells in mice with
appropriate mutations identified in the
human disease results in brain tumor
models that recapitulate human tumors
(Gibson et al., 2010; Johnson et al., 2010;
Gilbertson, 2011). This approach allows for the application of
these model systems in high-throughput drug screens of new
treatments that can be rapidly translated to the clinic (Atkinson et
al., 2011).
The R.J.G. laboratory has adapted this same approach to in-
crease understanding of the biology and treatment of pediatric
choroid plexus carcinoma (CPC). In a collaboration involving
experts in brain tumor biology, neurobiology, genomics, neuro-
pathology, and drug development, they have used in utero elec-
troporation to develop a new and highly flexible model of CPC.
Comprehensive histologic and genomic analyses of these tumors
have validated these mouse tumors as faithful models of human
CPC and enabled the identification of nonrandom large chro-
mosomal and focal alterations that are secondary events in the
development of CPCs. Further in utero electroporation studies
of these aberrantly altered genes have identified those that
alter normal ChP development and might therefore impact
CPC formation. Finally, cells from this CPC model have been
adapted for high-throughput drug screens. To date, mouse
models have been screened against 1.2 million compounds,
identifying numerous highly active novel agents for further
preclinical testing, which we hope will improve the survival of
children with CPC.
CSF in Alzheimer’s disease
Recent studies suggest that theChP-CSF systemplays central roles in
Alzheimer’s disease (AD), themost commoncause of dementia. It is
estimated that there are30millioncasesofADworldwide, and this
number will triple in the next 40 years unless a disease-modifying
therapy is developed (Holtzman et al., 2011). An important series of
findings over the last 25 years in both the rare forms of early-onset,
dominantly inherited AD (1% of AD) as well as in the common
late-onsetAD(age of onset60,99%ofAD) is that the pathology
underlying the disease begins to develop15 years before the onset
of cognitive decline. By the time that cognitive decline is present,
there is not only substantial amyloid- (A) deposition in the form
of amyloid plaques, there is also tau aggregation in the form of neu-
rofibrillary tangles, neuroinflammation, and neuronal and synaptic
loss in certain brain regions (Fagan et al., 2009; Perrin et al., 2009).
Thus, although our understanding of the pathogenesis of AD has
greatly increased, if we are to develop effective treatments that can
delay the onset or slow AD, it will be critical to accurately diagnose
Figure 3. ChP-secreted signals instruct neurogenesis. A, In the developing embryonic brain, the ChP secretes a library of
signaling activities, including insulin-like growth factor 2 (IGF2). CSF-IGF2 binds to the apical surface of cerebral cortical progenitor
cells (neuroepithelial cells [NEC]; radial glial cells [RG]) located in the ventricular zone (VZ) immediately adjacent to the CSF, and to
their primary cilia (arrowhead),whichextend into theCSF. CSF-IGF2 instructs progenitor cell division in anage-dependentmanner.
B, In the adult brain, the ChP secretesmany factors into the CSF, including the cytokine IL-1. CSF-IL-1 regulates the quiescence
of adult neural stem cells (B cells), which contact the CSF via a primary cilium (arrowhead), while retaining contact with blood
vessels (BV). E, Ependymal cells; C, transit amplifying cells; A, neuroblasts.
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AD both in its early clinical stages as well as before the onset of
cognitive decline (preclinical AD).
Dynamic and static assessments of several CSF proteins have
proven to be very useful in detecting different aspects of AD
pathology as well as in identifying fundamental aspects of protein
metabolism relevant to AD. CSF levels of A42 decrease with the
onset of A deposition in the brain beginning 10–15 years
before the onset of cognitive decline. This is the result of an
equilibrium between soluble monomeric A42 in CSF, brain in-
terstitial fluid, and amyloid plaques (Fig. 2). CSF tau and phos-
phorylated forms of tau increase in CSF 5–10 years before
cognitive decline, probably because of an increase in tau release
from neurons related in some way to neurodegeneration. The
combination of these changes can predict the rate of decline in
individuals who have mild cognitive impairment/very mild de-
mentia resulting from AD, as well as the conversion from cogni-
tive normality to dementia over a 5-year period. In addition to
tau, anothermarker of neurodegeneration in CSF is the neuronal
protein VILIP-1 (Tarawneh et al., 2011), which has similar diag-
nostic and prognostic value to tau in AD. In addition to static
measurement of these proteins in CSF, using metabolic labeling
with 13C-labeled amino acids, the synthesis and clearance rate of
A are extremely rapid in the CNS/CSF (on the order of hours)
(Bateman et al., 2006). Interestingly, the clearance rate of A
appears to be slower in individuals with AD compared with age-
matched controls, suggesting that slowed A clearance may be
central in causing late-onset AD. In dominantly inherited early-
onset AD, the production rate of A42 relative to A40 is ele-
vated in many individuals as predicted (Potter et al., 2013).
However, the turnover rate of CSF A42 is faster in these indi-
viduals if they already have amyloid plaques, suggesting active
deposition of soluble A42 into plaques. Together, these findings
suggest that the kinetics of biomarker availability in the CSF serve
as a harbinger of cognitive fitness, opening avenues toward the
possibility of harnessing the CSF for tailoring personalized ther-
apeutic approaches for detecting, diagnosing, and treating AD in
the aging brain.
Choroid plexus in therapy
Despite themany recent advances inmedicine, effective therapies
for most CNS diseases remain few and far between. The reasons
for this aremany but include the complexities of the human CNS
itself and the many difficulties in getting therapeutic compounds
past CNS barriers, particularly the blood-brain barrier (BBB).
Because there is no CSF–brain barrier (Goldmann, 1913), CNS
delivery past these barriers can be achieved clinically by direct
injections into the CSF (intrathecal or intraventricular) (e.g.,
Dickson et al., 2007). However, such injections come with mul-
tiple downsides, such as the many repeated treatments needed
over a lifetime and associated safety issues. Cell-based therapies
that are long-lived, safe, and provide long-term delivery to the
CSF would circumvent these issues and could represent ideal
therapeutic strategies for treatingmany CNS diseases. The prom-
ise of ChP-based therapies has been shown using transplanted
primary choroid plexus (e.g., encapsulated porcine ChP)
(Thanos et al., 2010) and ChP-tropic AAV viruses (Haskell et al.,
2003), although these approaches also have inherent limitations
(e.g., Manno et al., 2006).
A stem cell-based approach for generating CPECs (patent
pending) (Watanabe et al., 2012) that could address many of
these limitations was recently described. CPECs are the work-
horse cells that perform the major secretory, transport, detoxifi-
cation, and barrier functions of the ChP. CPECs are born to
secrete CSF, normally producing 400–600 ml (approximately 2
cups) of CSF every day in humans, which is continuous with
brain interstitial fluid across ependymal, pial, and certain
perivascular surfaces (Serot et al., 2000; Emerich et al., 2005) (Fig.
2). In vivo, CPECs are long-lived, exhibiting little proliferation or
turnover; accordingly, primary CPECs have been difficult to ex-
pand in culture to a significant degree (Watanabe et al., 2012).
Using ES cells as starting material (which circumvents the
expandability problem), the production of derived CPECs
(dCPECs) follows important developmental principles, such as the
ability of BMP4 to act as an instructive morphogen for CPEC fate
(Cheng et al., 2006; Hu et al., 2008) and the restriction of CPEC
potential to early-stage neuroepithelial cells rather than later-stage
radial glia (Thomas andDziadek, 1993). Importantly, both primary
and dCPECs can integrate readily into host ChP after intraventricu-
lar injection (Watanabe et al., 2012), which represents an attractive
and clinically feasible approach for dCPEC-based therapies (Fig. 2).
Given that multiple highly expressed CPEC gene loci have been
identified (e.g., the TRANSTHYRETIN gene), genetic engineering
approaches to produce high levels of therapeutic proteins or pep-
tides for natural, safe, and long-term delivery into the CNS should
now be feasible. The ability to generate and engineer dCPECs could
represent transformative approaches for treating a wide range of
CNS diseases. In addition, given the lack of significant barriers be-
tween the bloodstream and the ChP itself, dCPECs provide a new,
clinically feasible target for drug screens and therapeutic strategies
that can bypass the BBB (Gonzalez et al., 2012).
In conclusion, the ChP-CSF system actively coordinates the
development and health of the nervous system throughout life.
The growing body of work on the ChP-CSF system summarized
in this minireviewmarks the beginning of a new era for studies of
this system. Understanding the constituency of the CSF and the
actions of the ChP-CSF system is important not only for guiding
basic biology and stem cell research but also for propelling cur-
rent and potential uses in pharmacologic and surgical therapies
for hydrocephalus, cancer, neurodegenerative disease, and be-
yond. Because the ChP-CSF system interacts with essentially ev-
ery other system in the CNS, we hope this “state of the field
address” provides inspiration for advancing past outdated con-
ceptual and technical barriers in the field, sparking initiatives that
will harness what the ChP-CSF system has to offer in service of
nervous system repair.
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